624. Probability of Target Attainment of Ceftolozane/Tazobactam Among Adult Patients with Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Secondary to Pseudomonas aerug...

por Okuma, Aline, Polis, Thales, Pavia, Jacqueline, Mizuno, Gustavo, Ferrari, Jacqueline, DeRyke, Charles A
Publicado 2022

1674. Trends in Antimicrobial Susceptibility to Ceftolozane/Tazobactam and Comparators of Pseudomonas aeruginosa from Patients with Respiratory Tract Infections in Five Latin Ameri...

por Lob, Sibylle, Hackel, Meredith, Siddiqui, Fakhar, Pavia, Jacqueline, DeRyke, Charles A, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Publicado 2022

1671. Activity of Imipenem/Relebactam and Comparators Against Gram-Negative MDR and DTR Pathogens from Patients with Respiratory and Bloodstream Infections – SMART United States 20...

por Lob, Sibylle, Hackel, Meredith, Siddiqui, Fakhar, Bauer, Karri A, DeRyke, Charles A, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Publicado 2022

1670. Activity of Ceftolozane/Tazobactam and Comparators Against Clinical MDR and DTR Pseudomonas aeruginosa isolates – SMART United States 2018-2020

por Lob, Sibylle, Hackel, Meredith, Siddiqui, Fakhar, Bauer, Karri A, DeRyke, Charles A, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Publicado 2022